DUBLIN–(BUSINESS WIRE)–The “Acromegaly
Treatment Market by Disease type , Diagnosis Type include Medical
Imaging and Medical Laboratory Test and Treatment Type include
Medication, surgery and Radiation Therapy: Global Forecast, 2016 – 2022”
report has been added to ResearchAndMarkets.com’s
The report covers forecast and analysis for the acromegaly treatment
market on a global and regional level. The study provides historic data
of 2016 along with a forecast from 2017-2022 based revenue USD Million.
The report provides company market share analysis in order to give a
broader overview of the key players in the market. In addition, the
report also covers key strategic developments of the market including
acquisitions mergers, agreements, partnerships, joint ventures
collaboration, research development and regional expansion of major
participants involved in the market on the global and regional basis.
The study covers price trend analysis, disease portfolio of various
companies according to the region.
The study provides a decisive view on acromegaly treatment market by
segmenting the market based on the disease type, diagnosis type,
treatment type and regions. All the segments have been analyzed based on
the present and future trends and the market is estimated from
2014-2022. Based on disease type the, the market is segmented into
ectopic acromegaly and pseudo acromegaly. Based on diagnosis type market
is segmented into medical imaging and medical laboratory tests. Based on
the treatment type market is segmented into surgery, drug therapy, and
- Pfizer Inc.
- Chiasma Inc.
- Novartis AG
- Ipsen Biopharmaceuticals Inc.
- Wockhardt Ltd.
- Troikaa Pharmaceuticals Limited
- VHB Life Sciences Limited
- GlaxoSmithKline plc
Key Topics Covered:
2. Executive Summary
3. Acromegaly treatment Market Dynamics
4. Global Acromegaly treatment Market Competitive Landscape
5. Global Acromegaly treatment Market Disease Type Segment Analysis
6. Global Acromegaly treatment Market Diagnosis Type Segment Analysis
7. Global Acromegaly treatment Market Regional Segment Analysis
8. Company Profile
For more information about this report visit https://www.researchandmarkets.com/research/bfk99s/acromegaly?w=4
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
and Metabolic Disorders Drugs